JP2013530146A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013530146A5 JP2013530146A5 JP2013511403A JP2013511403A JP2013530146A5 JP 2013530146 A5 JP2013530146 A5 JP 2013530146A5 JP 2013511403 A JP2013511403 A JP 2013511403A JP 2013511403 A JP2013511403 A JP 2013511403A JP 2013530146 A5 JP2013530146 A5 JP 2013530146A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- tissue
- cell
- domain
- activation domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims 59
- 108020001507 fusion proteins Proteins 0.000 claims 59
- 210000004027 cell Anatomy 0.000 claims 30
- 230000004913 activation Effects 0.000 claims 28
- 230000008685 targeting Effects 0.000 claims 23
- 210000001519 tissue Anatomy 0.000 claims 19
- 230000004083 survival effect Effects 0.000 claims 9
- 102000009465 Growth Factor Receptors Human genes 0.000 claims 8
- 108010009202 Growth Factor Receptors Proteins 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims 5
- 210000000130 stem cell Anatomy 0.000 claims 5
- 230000017423 tissue regeneration Effects 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 3
- 210000004899 c-terminal region Anatomy 0.000 claims 3
- 210000001723 extracellular space Anatomy 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 102000005962 receptors Human genes 0.000 claims 3
- 108020003175 receptors Proteins 0.000 claims 3
- 230000008929 regeneration Effects 0.000 claims 3
- 238000011069 regeneration method Methods 0.000 claims 3
- 102000000412 Annexin Human genes 0.000 claims 2
- 108050008874 Annexin Proteins 0.000 claims 2
- 101710199268 Periostin Proteins 0.000 claims 2
- 102100037765 Periostin Human genes 0.000 claims 2
- 102000001708 Protein Isoforms Human genes 0.000 claims 2
- 108010029485 Protein Isoforms Proteins 0.000 claims 2
- 102000007501 Thymosin Human genes 0.000 claims 2
- 108010046075 Thymosin Proteins 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 230000008520 organization Effects 0.000 claims 2
- 229920002704 polyhistidine Polymers 0.000 claims 2
- -1 stem cell factor Proteins 0.000 claims 2
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 claims 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 102000004121 Annexin A5 Human genes 0.000 claims 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 102100032528 C-type lectin domain family 11 member A Human genes 0.000 claims 1
- 101710167766 C-type lectin domain family 11 member A Proteins 0.000 claims 1
- 102000013602 Cardiac Myosins Human genes 0.000 claims 1
- 108010051609 Cardiac Myosins Proteins 0.000 claims 1
- 101800003838 Epidermal growth factor Proteins 0.000 claims 1
- 102400001368 Epidermal growth factor Human genes 0.000 claims 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 1
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 claims 1
- 102100039064 Interleukin-3 Human genes 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000017761 Interleukin-33 Human genes 0.000 claims 1
- 108010067003 Interleukin-33 Proteins 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 102100039648 Lactadherin Human genes 0.000 claims 1
- 101710191666 Lactadherin Proteins 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 1
- 102000014413 Neuregulin Human genes 0.000 claims 1
- 108050003475 Neuregulin Proteins 0.000 claims 1
- 108090000556 Neuregulin-1 Proteins 0.000 claims 1
- 102400000058 Neuregulin-1 Human genes 0.000 claims 1
- 108010035766 P-Selectin Proteins 0.000 claims 1
- 102100023472 P-selectin Human genes 0.000 claims 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 1
- 102000007584 Prealbumin Human genes 0.000 claims 1
- 108010071690 Prealbumin Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000007562 Serum Albumin Human genes 0.000 claims 1
- 108010071390 Serum Albumin Proteins 0.000 claims 1
- 108010039445 Stem Cell Factor Proteins 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 102000001317 Synaptotagmin I Human genes 0.000 claims 1
- 108010055170 Synaptotagmin I Proteins 0.000 claims 1
- 101710098080 Teratocarcinoma-derived growth factor Proteins 0.000 claims 1
- 102000036693 Thrombopoietin Human genes 0.000 claims 1
- 108010041111 Thrombopoietin Proteins 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 claims 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 230000003172 anti-dna Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000004071 biological effect Effects 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 208000037887 cell injury Diseases 0.000 claims 1
- 230000009087 cell motility Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000006041 cell recruitment Effects 0.000 claims 1
- 102000003675 cytokine receptors Human genes 0.000 claims 1
- 108010057085 cytokine receptors Proteins 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000010494 dissociation reaction Methods 0.000 claims 1
- 230000005593 dissociations Effects 0.000 claims 1
- 229940116977 epidermal growth factor Drugs 0.000 claims 1
- 229940126864 fibroblast growth factor Drugs 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 210000003630 histaminocyte Anatomy 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 claims 1
- 229940053128 nerve growth factor Drugs 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34704010P | 2010-05-21 | 2010-05-21 | |
| US61/347,040 | 2010-05-21 | ||
| PCT/US2011/037459 WO2011146902A1 (en) | 2010-05-21 | 2011-05-20 | Bi-specific fusion proteins |
| US13/068,808 US9238080B2 (en) | 2010-05-21 | 2011-05-20 | Bi-specific fusion proteins |
| US13/112,907 US8691771B2 (en) | 2010-05-21 | 2011-05-20 | Bi-specific fusion proteins for tissue repair |
| US13/112,907 | 2011-05-20 | ||
| US13/068,808 | 2011-05-20 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016130526A Division JP6174763B2 (ja) | 2010-05-21 | 2016-06-30 | 二重特異的融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013530146A JP2013530146A (ja) | 2013-07-25 |
| JP2013530146A5 true JP2013530146A5 (https=) | 2014-07-03 |
| JP6200806B2 JP6200806B2 (ja) | 2017-09-20 |
Family
ID=44972647
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511403A Active JP6200806B2 (ja) | 2010-05-21 | 2011-05-20 | 二重特異的融合タンパク質 |
| JP2016130526A Active JP6174763B2 (ja) | 2010-05-21 | 2016-06-30 | 二重特異的融合タンパク質 |
| JP2017132859A Active JP6822911B2 (ja) | 2010-05-21 | 2017-07-06 | 二重特異的融合タンパク質 |
| JP2019117073A Active JP6965311B2 (ja) | 2010-05-21 | 2019-06-25 | 二重特異的融合タンパク質 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016130526A Active JP6174763B2 (ja) | 2010-05-21 | 2016-06-30 | 二重特異的融合タンパク質 |
| JP2017132859A Active JP6822911B2 (ja) | 2010-05-21 | 2017-07-06 | 二重特異的融合タンパク質 |
| JP2019117073A Active JP6965311B2 (ja) | 2010-05-21 | 2019-06-25 | 二重特異的融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (11) | US8691771B2 (https=) |
| EP (1) | EP2571992B1 (https=) |
| JP (4) | JP6200806B2 (https=) |
| CN (1) | CN103124788B (https=) |
| AU (1) | AU2011255238B2 (https=) |
| BR (1) | BR112012029611A2 (https=) |
| CA (1) | CA2800173C (https=) |
| ES (1) | ES2674567T3 (https=) |
| WO (1) | WO2011146902A1 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010059315A1 (en) * | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| KR101722961B1 (ko) | 2009-02-11 | 2017-04-04 | 알부메딕스 에이/에스 | 알부민 변이체 및 접합체 |
| EP2493921B1 (en) | 2009-10-30 | 2018-09-26 | Albumedix Ltd | Albumin variants |
| KR20130020765A (ko) | 2010-02-16 | 2013-02-28 | 메디뮨 엘엘씨 | Ｈｓａ-관련 조성물 및 사용방법 |
| EP2556087A1 (en) | 2010-04-09 | 2013-02-13 | Novozymes Biopharma DK A/S | Albumin derivatives and variants |
| EP2571992B1 (en) | 2010-05-21 | 2018-04-25 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| CN103987401A (zh) * | 2011-04-28 | 2014-08-13 | 范斯坦医药研究院 | Mfg-e8及其用途 |
| CA2830660A1 (en) | 2011-05-05 | 2012-11-08 | Novozymes Biopharma Dk A/S | Albumin variants |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| DK2825556T3 (en) | 2012-03-16 | 2018-04-16 | Albumedix As | albumin Variants |
| AU2013263349B2 (en) | 2012-05-17 | 2016-09-08 | Extend Biosciences, Inc | Carriers for improved drug delivery |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| CN104619727B (zh) * | 2012-06-25 | 2019-04-05 | 布里格姆及妇女医院股份有限公司 | 靶向治疗 |
| WO2014036520A1 (en) | 2012-08-30 | 2014-03-06 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
| MX2015005363A (es) | 2012-11-08 | 2015-11-06 | Novozymes Biopharma Dk As | Variantes de albumina. |
| CN105518143B (zh) * | 2013-03-15 | 2020-02-21 | 北京凯得尔森生物技术有限公司 | 融合蛋白分子和它的使用方法 |
| EP4299595A3 (en) | 2014-05-02 | 2024-03-13 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
| EP3157947A1 (en) * | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
| US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| JP2018513155A (ja) | 2015-04-17 | 2018-05-24 | メリマック ファーマシューティカルズ インコーポレーティッド | セリバンツマブを用いた併用療法 |
| CN104946656B (zh) * | 2015-06-08 | 2018-08-17 | 吉林省农业科学院 | 一种人源碱性成纤维细胞生长因子、烟草叶绿体表达载体及生产方法 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| JP7007261B2 (ja) | 2015-08-20 | 2022-01-24 | アルブミディクス リミティド | アルブミン変異体及びコンジュゲート |
| GB2542391A (en) * | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
| CN108367048B (zh) | 2015-10-02 | 2022-08-12 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
| WO2017107914A1 (zh) * | 2015-12-21 | 2017-06-29 | 合肥立方制药股份有限公司 | 一种药物设计方法和获得的药物及其应用 |
| EP3400069A4 (en) * | 2016-01-04 | 2019-09-25 | Cour Pharmaceuticals Development Company Inc. | Particles for the Encapsulation of Fusion Proteins with Bundled Epitopes |
| IL313507A (en) | 2016-02-03 | 2024-08-01 | Amgen Res Munich Gmbh | Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof |
| EA201891753A1 (ru) | 2016-02-03 | 2019-01-31 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкции антител к psma и cd3, вовлекающие т-клетки |
| EP3423572B1 (en) | 2016-03-02 | 2023-11-29 | Momenta Pharmaceuticals, Inc. | Methods related to engineered fc constructs |
| AU2017235450A1 (en) | 2016-03-15 | 2018-08-16 | Merrimack Pharmaceuticals, Inc. | Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody |
| DK3484514T3 (da) | 2016-05-23 | 2024-01-29 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
| JP7146771B2 (ja) | 2017-01-06 | 2022-10-04 | モメンタ ファーマシューティカルズ インコーポレイテッド | 操作されたＦｃコンストラクトに関する組成物及び方法 |
| JP2020530280A (ja) * | 2017-07-03 | 2020-10-22 | トルク セラピューティクス， インコーポレイテッド | 免疫刺激性融合分子およびその使用 |
| EP3658186A4 (en) * | 2017-07-24 | 2020-08-12 | Rutgers, The State University of New Jersey | FUSION MOLECULES TARGETING PHOSPHATIDYLSERINE AND THEIR METHODS OF USE |
| CN107880133A (zh) * | 2017-11-04 | 2018-04-06 | 海南大学 | 促皮质素与胰岛素样生长因子1融合蛋白及其制备方法 |
| US11464803B2 (en) * | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| GB201919019D0 (en) * | 2019-12-20 | 2020-02-05 | Autolus Ltd | Antigen-binding domain |
| WO2021160267A1 (en) * | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd7 |
| EP4103612A1 (en) * | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Bispecific antibodies against cd9 |
| US20220031812A1 (en) * | 2020-07-30 | 2022-02-03 | Silver Creek Pharmaceuticals, Inc. | Chimeric Proteins and Methods of Use for Treatment of Central Nervous System Disorders |
| CN112266417B (zh) * | 2020-10-27 | 2022-02-11 | 温州医科大学 | 一种以结缔组织生长因子为靶点的全人源拮抗抗体及其应用 |
| WO2022092974A1 (ko) * | 2020-10-30 | 2022-05-05 | (주)셀레메디 | 항체 유사 단백질 및 그 용도 |
| US11946055B2 (en) * | 2020-12-10 | 2024-04-02 | The Regents Of The University Of California | Protein engineering via error-prone orthogonal replication and yeast surface display |
| JP2024519578A (ja) * | 2021-05-03 | 2024-05-17 | セレメディー カンパニー，リミテッド | 新規タンパク質 |
| US20240141001A1 (en) * | 2021-06-14 | 2024-05-02 | Institut National de la Santé et de la Recherche Médicale | Mutated annexin a5 polypeptides and uses thereof for therapeutic purposes |
| CN117659178B (zh) * | 2022-08-23 | 2024-09-24 | 东莞市朋志生物科技有限公司 | 抗甲型流感病毒抗体或其功能性片段、检测甲型流感病毒的试剂和试剂盒 |
| KR20250075704A (ko) | 2022-09-30 | 2025-05-28 | 익스텐드 바이오사이언시즈, 인크. | 장기-지속형 부갑상선 호르몬 |
| CN118420712A (zh) * | 2023-02-01 | 2024-08-02 | 上海健信生物医药科技有限公司 | 一种三特异性抗体技术平台及其应用 |
| CN116983407B (zh) * | 2023-08-03 | 2025-10-28 | 艾可泰科(浙江)控股有限公司 | 一种治疗膝关节炎的新一代干细胞治疗剂及其制备工艺 |
| CN117736344B (zh) * | 2024-01-30 | 2024-06-21 | 南通大学 | 具有自组装性能的重复结构单元重组蛋白ⅡAⅡB-ⅡAⅡBrQTY及应用 |
| CN121379975B (zh) * | 2025-12-25 | 2026-04-17 | 天津一瑞生物科技股份有限公司 | 抗TcdB毒素杂交瘤细胞株、单克隆抗体及应用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8819826D0 (en) | 1988-08-20 | 1988-09-21 | Kabivitrum Ab | Glycosylated igf-1 |
| US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US5679771A (en) | 1990-02-13 | 1997-10-21 | Gropep Pty. Ltd. | Method for treating intestinal diseases |
| US6566098B1 (en) | 1990-09-14 | 2003-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA encoding truncated hepatocyte growth factor variants |
| DE69133036T2 (de) | 1990-11-09 | 2003-02-06 | Stephen D. Gillies | Cytokine immunokonjugate |
| US5632986A (en) | 1991-05-09 | 1997-05-27 | The University Of Washington | Phospholipid-targeted thrombolytic agents |
| WO1994028133A1 (en) * | 1993-05-21 | 1994-12-08 | Amgen Inc. | Recombinant neu differentiation factors |
| WO1995032003A1 (en) | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| US5780052A (en) * | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
| CA2224859A1 (en) | 1996-04-17 | 1997-10-23 | Amitabh Gaur | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| US7067109B1 (en) * | 1998-07-13 | 2006-06-27 | Board Of Regents, The University Of Texas System | Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids |
| US6387663B1 (en) * | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| JP2002535967A (ja) | 1999-01-06 | 2002-10-29 | ジェネンテック・インコーポレーテッド | インシュリン様成長因子（ｉｇｆ）ｉ変異体 |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| ATE316980T1 (de) | 1999-07-21 | 2006-02-15 | Univ Southern California | Fusions-polypeptide zur gewebegeneration und wundheilung zur gezielten matrixanwendung |
| GB2360771A (en) * | 2000-03-28 | 2001-10-03 | Antisoma Res Ltd | Compounds for targeting |
| ATE463252T1 (de) | 2000-08-29 | 2010-04-15 | Aurogen Inc | Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf |
| ME00502B (me) * | 2001-01-05 | 2011-10-10 | Amgen Fremont Inc | Antitjela za insulinu sličan receptor faktora i rasta |
| US7635680B2 (en) * | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
| WO2002087510A2 (en) | 2001-04-30 | 2002-11-07 | Symbiontics, Inc. | Subcellular targeting of therapeutic proteins |
| US7049286B2 (en) * | 2001-08-30 | 2006-05-23 | Diatos, S.A. | Insulin conjugates and methods of use thereof |
| AU2008200706B2 (en) | 2001-10-16 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| EP1622645B1 (en) | 2002-04-23 | 2013-10-23 | Roger Williams Hospital | Compositions and methods for stem cell delivery |
| EP1509541B1 (en) | 2002-06-06 | 2011-11-23 | Tze Chein Wun | Novel recombinant anticoagulant proteins |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20040213738A1 (en) | 2003-03-31 | 2004-10-28 | Susan Croll-Kalish | CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity |
| WO2004100961A1 (ja) | 2003-05-19 | 2004-11-25 | Seikagaku Corporation | 硫酸基転移酵素阻害剤 |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| ES2383300T3 (es) | 2003-11-13 | 2012-06-20 | Hanmi Holdings Co., Ltd | Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación |
| EP1702069A2 (en) * | 2004-01-05 | 2006-09-20 | EMD Lexigen Research Center Corp. | Interleukin-12 targeted to oncofoetal fibronectin |
| HUE027902T2 (en) * | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| BRPI0510716A (pt) * | 2004-05-05 | 2007-11-20 | Merrimack Pharmaceuticals Inc | uso de um agente de ligação bi-especìfico, agente de ligação bi-especìfico, composição de um agente de ligação bi-especìfico, e, kit |
| WO2006004910A2 (en) | 2004-06-28 | 2006-01-12 | Transtarget Inc. | Improved bispecific antibodies |
| US7511016B2 (en) | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| US7531318B2 (en) | 2004-08-20 | 2009-05-12 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
| JP2008510732A (ja) | 2004-08-20 | 2008-04-10 | ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システム | 心臓組織の損傷を処置、予防、阻害、または緩和する方法 |
| WO2006047214A2 (en) | 2004-10-21 | 2006-05-04 | Igf Oncology, Llc | Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer |
| SG158153A1 (en) * | 2004-12-21 | 2010-01-29 | Musc Found For Res Dev | Compositions and methods for promoting wound healing and tissue regeneration |
| JP4988599B2 (ja) | 2005-01-07 | 2012-08-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｉｇｆ−１融合ポリペプチドおよびその治療的使用 |
| EP1841467A4 (en) * | 2005-01-14 | 2009-01-28 | Cytogen Corp | COMBINATION CANCER THERAPY WITH ANTI-PSMA ANTIBODIES |
| CN101146826A (zh) * | 2005-01-24 | 2008-03-19 | 得克萨斯大学体系董事会 | 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途 |
| CA2599606A1 (en) | 2005-02-23 | 2006-08-31 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents for modulating biological activity |
| US7521211B2 (en) * | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| US20070054851A1 (en) * | 2005-05-27 | 2007-03-08 | Junyu Lin | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases |
| WO2007021494A2 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| NZ569078A (en) | 2005-12-12 | 2012-01-12 | Mosamedix Bv | Annexin derivatives suitable for pretargeting in therapy and diagnosis |
| US7776816B2 (en) | 2006-01-20 | 2010-08-17 | Board Of Regents, The University Of Texas System | Preserving hypoxic tissue |
| CA2638811A1 (en) * | 2006-02-03 | 2007-08-16 | Medimmune, Llc | Protein formulations |
| MX2008010561A (es) | 2006-02-15 | 2009-03-02 | Imclone Systems Inc | Anticuerpos funcionales. |
| CA2646508A1 (en) * | 2006-03-17 | 2007-09-27 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| US9187517B2 (en) | 2006-11-13 | 2015-11-17 | The Brigham And Women's Hospital, Inc. | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
| US8003761B2 (en) | 2007-01-23 | 2011-08-23 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
| SE530073C2 (sv) | 2007-01-23 | 2008-02-26 | Teknikbolaget K Samuelsson Ab | Sprutmunstycksanordning för brandsläckningssystem |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| EP2152751A1 (en) | 2007-05-31 | 2010-02-17 | Genmab A/S | Fusion or linked proteins with extended half life |
| US8889140B2 (en) | 2007-05-31 | 2014-11-18 | Transtarget, Inc. | Compositions and methods for tissue repair |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| WO2009030720A2 (en) | 2007-09-06 | 2009-03-12 | Novozymes Biopharma Dk A/S | Process for producing a recombinant protein |
| MX2010011145A (es) | 2008-04-11 | 2011-04-11 | Merrimack Pharmaceuticals Inc | Enlazadores de la albumina de suero humana y conjugados de la misma. |
| WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
| WO2010087976A2 (en) | 2009-01-31 | 2010-08-05 | Igf Oncology, Llc | Anti-cancer protein-platinum conjugates |
| WO2011011072A2 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) having amino acid substitution at position 59 |
| WO2011011071A2 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
| AU2010306774A1 (en) | 2009-10-14 | 2012-05-03 | Merrimack Pharmaceuticals, Inc. | Bispecific binding agents targeting IGF-1R and ErbB3 signalling and uses thereof |
| EP2493921B1 (en) | 2009-10-30 | 2018-09-26 | Albumedix Ltd | Albumin variants |
| EP2571992B1 (en) | 2010-05-21 | 2018-04-25 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| ES2690663T3 (es) | 2010-12-08 | 2018-11-21 | Viacyte, Inc. | Agentes y métodos para inhibir el crecimiento de células madre pluripotentes humanas |
| EP2780364A2 (en) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| CN104011070A (zh) | 2011-12-15 | 2014-08-27 | 爱德迪安（北京）生物技术有限公司 | 具有降血糖作用的化合物、组合物及其用途 |
| EP3395358B1 (en) | 2012-09-26 | 2019-11-06 | Indiana University Research and Technology Corporation | Insulin analog dimers |
| HK1220903A1 (zh) | 2013-03-29 | 2017-05-19 | Merrimack Pharmaceuticals, Inc. | 软骨结合型融合蛋白 |
| CA2936675C (en) | 2014-01-12 | 2023-06-27 | Igf Oncology, Llc | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
| CN108367048B (zh) * | 2015-10-02 | 2022-08-12 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
| EP3857888A4 (en) | 2018-10-06 | 2022-08-03 | HFI Innovation Inc. | METHOD AND APPARATUS FOR AN AREA OF A SHARED MERGER CANDIDATE LIST FOR ENABLING VIDEO CODING |
-
2011
- 2011-05-20 EP EP11729797.8A patent/EP2571992B1/en active Active
- 2011-05-20 AU AU2011255238A patent/AU2011255238B2/en active Active
- 2011-05-20 JP JP2013511403A patent/JP6200806B2/ja active Active
- 2011-05-20 ES ES11729797T patent/ES2674567T3/es active Active
- 2011-05-20 US US13/112,907 patent/US8691771B2/en active Active
- 2011-05-20 US US13/068,808 patent/US9238080B2/en active Active
- 2011-05-20 CA CA2800173A patent/CA2800173C/en active Active
- 2011-05-20 BR BR112012029611A patent/BR112012029611A2/pt not_active Application Discontinuation
- 2011-05-20 WO PCT/US2011/037459 patent/WO2011146902A1/en not_active Ceased
- 2011-05-20 CN CN201180035656.1A patent/CN103124788B/zh active Active
-
2014
- 2014-02-24 US US14/187,728 patent/US9982060B2/en active Active
-
2015
- 2015-12-14 US US14/967,980 patent/US9718892B2/en active Active
-
2016
- 2016-06-30 JP JP2016130526A patent/JP6174763B2/ja active Active
-
2017
- 2017-06-09 US US15/618,478 patent/US10407512B2/en active Active
- 2017-07-06 JP JP2017132859A patent/JP6822911B2/ja active Active
-
2018
- 2018-04-19 US US15/957,252 patent/US10858450B2/en active Active
-
2019
- 2019-06-25 JP JP2019117073A patent/JP6965311B2/ja active Active
- 2019-07-29 US US16/524,451 patent/US10988547B2/en active Active
-
2020
- 2020-10-23 US US17/078,978 patent/US11673970B2/en active Active
-
2021
- 2021-03-25 US US17/212,270 patent/US11814443B2/en active Active
-
2023
- 2023-05-03 US US18/311,306 patent/US20230322951A1/en active Pending
- 2023-10-09 US US18/483,308 patent/US20240101713A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013530146A5 (https=) | ||
| JP2019196365A5 (https=) | ||
| JP2017000143A5 (https=) | ||
| ES2788394T3 (es) | Péptido para inducir regeneración de tejido y uso del mismo | |
| Saraf et al. | Gene delivery strategies for cartilage tissue engineering | |
| Won et al. | Cell surface engineering to enhance mesenchymal stem cell migration toward an SDF-1 gradient | |
| Kim et al. | Irradiation enhances the tumor tropism and therapeutic potential of tumor necrosis factor-related apoptosis-inducing ligand-secreting human umbilical cord blood-derived mesenchymal stem cells in glioma therapy | |
| Santos et al. | Osteogenic differentiation of mesenchymal stem cells using PAMAM dendrimers as gene delivery vectors | |
| Assal et al. | The promotion of angiogenesis by growth factors integrated with ECM proteins through coiled-coil structures | |
| Rey-Rico et al. | Effective and durable genetic modification of human mesenchymal stem cells via controlled release of rAAV vectors from self-assembling peptide hydrogels with a maintained differentiation potency | |
| JP2013541335A5 (https=) | ||
| CN105524176B (zh) | 双特异性融合蛋白 | |
| Lin et al. | Multidomain synthetic peptide B2A2 synergistically enhances BMP‐2 in vitro | |
| CA2848851C (en) | Wnt7a compositions and methods of using the same | |
| Choi et al. | The mineralization inducing peptide derived from dentin sialophosphoprotein for bone regeneration | |
| Lee et al. | Selective interference targeting of Lnk in umbilical cord-derived late endothelial progenitor cells improves vascular repair, following hind limb ischemic injury, via regulation of JAK2/STAT3 signaling | |
| CN107073063A (zh) | 用于修复软骨损伤的方法 | |
| Frisch et al. | Genetic modification of human peripheral blood aspirates using recombinant adeno-associated viral vectors for articular cartilage repair with a focus on chondrogenic transforming growth factor-β gene delivery | |
| Hashemibeni et al. | Investigation and comparison of the effect of TGF-β3, kartogenin and avocado/soybean unsaponifiables on the in-vitro and in-vivo chondrogenesis of human adipose-derived stem cells on fibrin scaffold | |
| Masumoto et al. | Hypoxia-responsive expression of vascular endothelial growth factor for induction of angiogenesis in artificial three-dimensional tissues | |
| CA2378925A1 (en) | Matrix-targeted fusion polypeptides for tissue regeneration and wound healing | |
| Papageorgis | Complex interplay between aging and cancer: role of TGF-β signaling | |
| Frisch et al. | Gene-and stem cell-based approaches to regulate hypertrophic differentiation in articular cartilage disorders | |
| RU2396342C1 (ru) | Способ получения трехмерных матриц для тканеподобных структур из клеток животного происхождения | |
| Trippel et al. | Gene therapy for articular cartilage repair |